Information Provided By: 
Fly News Breaks for June 7, 2017
HZNP
Jun 7, 2017 | 07:22 EDT
UBS analyst Marc Goodman believes the recent downward move for Horizon Pharma shares was due to frustration by investors who have grown tired of the lack of performance by the company, management's lowered guidance due to lack of visibility, and problems with the company's primary care businesses. Goodman believes the recent weakness is a buying opportunity, though he lowered his price target to $16 from $22 based on his sum-of-the-parts valuation. Goodman maintained his Buy rating on Horizon Pharma shares.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
